力生制药：上半年净利润3.43亿元 同比增长235.04%

Core Viewpoint - The company reported a mixed performance in its 2025 semi-annual report, with a slight decline in revenue but a significant increase in net profit [1] Financial Performance - The company achieved an operating revenue of 732 million yuan in the first half of the year, representing a year-on-year decrease of 1.76% [1] - The net profit attributable to the parent company was 343 million yuan, showing a substantial year-on-year increase of 235.04% [1] - Basic earnings per share were reported at 1.33 yuan [1] Subsidiary Performance - The subsidiary, Biochemical Pharmaceutical, experienced strong performance through coordinated domestic and international trade efforts [1] - Sales revenue from injectable urokinase increased by 14% [1] - Domestic sales of heparin sodium injection grew by over 18%, while international sales surged by 48% year-on-year [1]